In May 2026, Humana confirmed a revision to its GAAP EPS guidance, lowering it to $8.36 while holding its Adjusted EPS at $9.00. This $0.64 delta is not a sign of operational failure, but rather the "cost of progress."
The primary driver is the company’s Value Creation Initiatives. Humana is currently spending heavily on restructuring its technology footprint and medical coding operations to combat the Star Ratings headwind. These are one-time "reset" costs-severance, asset impairments, and consulting fees-that GAAP requires to be reported, but which do not reflect the day-to-day health of the insurance business. For the long-term investor, the stable $9.00 Adjusted EPS is the North Star, suggesting that the core machine is still generating cash as expected.